Recently, the programmed cell death protein 1 (PD‐1)‐targeting immune checkpoint inhibitors (ICIs; e.g., nivolumab and pembrolizumab) have shown significant efficacy among some patients with CRC.3, 5, 7, 8. Here, PDCD1 is linked to colorectal carcinoma.